M. Abdelrahim

Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma

Background Pancreatic adenocarcinoma (PDAC) is one of the most aggressive cancer histologies, as evidenced by high recurrence rate (85%) and poor 5-year overall survival...

M. Abdelrahim ;

A. Esmail ;

T. Katz ;

S. Sharma , MD;

E. Kalashnikova ;

Manoj Malhotra , MD;

P. Olshan ;

P. Billings ;

A. Aleshin ;

06/28/2021

Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma

Background Hepatocellular carcinoma HCC is the third leading cause of cancer death worldwide with more than 230,000 cases of HCC since 2000 and an estimated 42,000 new c...

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

K. Heyne ;

R. Ghobrial ;

M. Abdelrahim ;

06/27/2022

Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria

Background Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. C...

M. Abdelrahim ;

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

G. OKane ;

06/27/2022

The feasibility of tumor recurrence detection in liver post-transplantation for patients with hepatocellular carcinoma via personalized, tumor-informed ctDNA testing

Background Hepatocellular carcinoma (HCC) is an aggressive malignancy for which liver transplantation can be curative. Unfortunately, ∼8-20% of HCC patients will go on t...

H. Dhani ;

V. Aushev ;

A. Jurdi ;

J. Starr ;

P. Gauthier ;

M. Abdelrahim ;

A. Esmail ;

A. Saharia ;

A. He ;

06/27/2022

Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma

Background The Cholangiocarcinoma treatment options are constantly being updated in view of existing evidence in order to establish practice guidelines and consensus sta...

M. Abdelrahim ;

A. Esmail ;

A. Saharia ;

J. Xu ;

G. Umoru ;

H. Al-Rawi ;

06/27/2022